Contributors: Marchesi, F.; Pimpinelli, F.; Giannarelli, D.; Ronchetti, L.; Papa, E.; Falcucci, P.; Pontone, M.; Di Domenico, E. G.; di Martino, S.; Laquintana, V.; Mandoj, C.; Conti, L.; Cordone, I.; La Malfa, A.; Viggiani, C.; Renzi, D.; Palombi, F.; Romano, A.; Pisani, F.; Gumenyuk, S.; Di Bella, O.; Vujovic, B.; Morrone, A.; Ciliberto, G.; Ensoli, F.; Mengarelli, A.
نبذة مختصرة : Patients with hematological malignancies are at risk of severe COVID-19 and candidate to priority vaccination policies, preferably with a mRNA vaccine. In light of ethical considerations and strict indications of Health Authorities (HA), also patients with ongoing lymphodepleting therapy underwent vaccination. In Italy, the national plan against COVID-19 required to proceed as soon as possible with the vaccination of hematological patients in treatment with immunosuppressive or myelosuppressive drugs or within six months from the end of such treatment, and of stem cell transplanted patients after three months from transplant.
Processing Request
No Comments.